
compani
feb pm et
summari lead produc prescript drug offer wide rang treatment
neurolog disord diabet cancer condit
nm price-to-earnings oper ep
risk assess reflect gener challeng
compani brand patent drug develop
regulatori risk howev off-set robust
apr ep estim base cfra oper earn
histor earn report compani report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
past perform indic futur perform reli upon
analysi prepar equiti analyst
feb pm stock trade
see sale rise billion
aid new product trulic taltz
cyramza jardianc see trulic
sale billion taltz sale million
cyramza sale million jardianc
sale million among older drug
see humalog forteo sale billion
billion respect alimta sale
declin billion april
complet respons letter baricitinib treat
addit dose safeti data
surpris fda non-approv
baricitinib olumi approv europ
februari januari
resubmit nda baricitinib
discuss fda previous
expect nda resubmiss would occur
earli decemb file
bla galcanezumab prevent
migrain adult
pharmaceut million deal
ad lasmiditan treat migrain
posit phase data lasmiditan
see ep
octob said explor potenti
sale spin-off unit
expect provid updat
elanco sale billion
second-largest anim health compani
view potenti move posit howev
note face price pressur key
diabet franchis separ think
solidli manag challeng period
signific patent expir
anticip steadi sale growth next
sever year expect launch new
product cautiou
goal juli reach deal
gener manufactur extend
exclus ciali septemb
think achiev annual sale
growth improv gross
margin oper expens improv
less octob fda
approv verzenio treat breast cancer
see sale billion
risk recommend target price
includ failur develop commerci
target price
ep estim slightli peer
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
compani
corpor overview co lead maker prescript drug offer wide rang
treatment neurolog disord diabet cancer condit compani anim health
busi oper elanco divis develop manufactur market product
food anim companion anim compani product sold approxim countri
compani endocrinolog product includ humalog insulin analog treatment diabet
humulin human insulin recombin dna origin treatment diabet trajenta
treatment type diabet jentadueto combin tablet linagliptin trajenta metformin
hydrochlorid use treatment type diabet jardianc treatment type diabet
approv europ japan trulic treatment type diabet approv
 europ glyxambi combin tablet linagliptin empagliflozin jardianc
treatment type diabet approv januari forteo treatment
osteoporosi postmenopaus women men high risk fractur glucocorticoid-induc
osteoporosi men postmenopaus women evista prevent treatment
osteoporosi postmenopaus women reduct risk invas breast cancer
postmenopaus women osteoporosi postmenopaus women high risk invas breast
cancer humatrop treatment human growth hormon defici certain pediatr growth
condit axiron topic solut testosteron appli underarm applic replac
therapi men certain condit associ defici absenc testosteron
compani neurosci product includ cymbalta treatment major depress disord
diabet peripher neuropath pain gener anxieti disord manag
fibromyalgia chronic musculoskelet pain due chronic low back pain chronic pain due
osteoarthr zyprexa treatment schizophrenia acut mix manic episod associ
bipolar disord bipolar mainten strattera treatment attention-deficit hyperact
disord prozac treatment major depress disord obsessive-compuls disord bulimia
nervosa panic disord amyvid radioact diagnost agent positron emiss tomographi
imag beta-amyloid neurit plaqu brain adult patient cognit impair
evalu alzheim diseas caus cognit declin
compani anim health segment includ food product anim rumensin cattl feed
addit improv feed effici growth also control prevent coccidiosi posilac
protein supplement improv milk product dairi cow paylean optaflexx lean
perform enhanc swine cattl respect tylan antibiot use control certain
diseas cattl swine poultri micotil pulmotil pulmotil ac antibiot use treat
respiratori diseas cattl swine poultri respect coban monteban maxiban anticoccidi
agent use poultri surmax sold maxu countri perform improv
swine poultri
compani product companion anim includ trifexi monthli chewabl tablet dog
kill flea prevent flea infest prevent heartworm diseas control intestin parasit
infect comforti chewabl tablet kill flea prevent flea infest dog
januari compani complet acquisit novarti anim health
novarti anim health product includ denagard antibiot control treatment
respiratori enter diseas swine poultri milbemax spectrum intestin wormer
given monthli also offer prevent heartworm sentinel outsid monthli tablet
prevent flea popul concurr prevent heartworm diseas treatment
roundworm hookworm whipworm dog atopica treatment chronic manifest
atop dermat dog symptomat treatment chronic allerg dermat cat
fortekor treatment congest heart failur dog reduct proteinurea associ
chronic kidney diseas cat
pipelin spend total billion billion billion billion
equal sale respect one highest
 d-to-sal ratio drug industri industri averag approxim sale august
compani pipelin new chemic entiti new molecular entiti
nme new biotech entiti nbe total six compound phase ii seven phase
two regulatori review
execut vice-president scienc
technolog presid
lilli research
vice presid
senior vice presid
redistribut reproduct prohibit without prior written permiss copyright cfra
compani
base cfra proprietari quantit model
stock rank overvalu
neutral sinc januari technic indic
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
compani
still think long-term prospect
remain one widest-margin
industri prospect enhanc
demograph growth elderli
account industri sale
new drug discoveri howev
number new molecular entiti approv
declin robust approv
sinc record
approv follow robust approv
approv
 pharmaceut index
declin versu rise
composit index year-to-d
juli pharmaceut index
declin vs rise
fundament outlook pharmaceut
sub-industri next month posit
top-lin pressur patent expir
mani top-sel drug bottom
anticip modest sale increas
follow growth see
modest advers impact foreign exchang
follow firm
 dollar late also see
expand sale new innov drug
therapi margin improv accru
cost restructur merger synergi ep
comparison also benefit common
see afford act
continu neg affect industri
margin see benefit includ improv
sale demand signific expans
insur popul accord
depart human servic
insur sinc law enact
howev presid trump republican
made effort repeal replac
arr uncertain compon
surviv particularli individu
mandat medicaid expans may
hous repres pass
ahca would result million
peopl uninsur compar
june senat unveil healthcar
plan better reconcili act
bcra howev senat yet vote
bill cbo estim million
peopl would uninsur compar
hous senat plan would
elimin individu mandat phase
medicaid expans
despit advers effect patent expir
regulatori pressur high drug price
base index
five-year market price perform feb
note sector sub-industri inform base
past perform indic futur perform
reli upon
compani
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
compani
keep target above-p
forward ep estim ep vs
ahead estim rais ep estim sale rose
driven trulic taltz see declin sale matur product
evalu option baricitnib includ new trial believ nda
resubmiss would least month away view recent patent deal
gener manufactur regard ciali posit exclus
compani announc derica rice execut vice presid
global servic chief financi offic retir end decemb
year servic compani rice also member
compani execut committe compani consid intern extern
candid succeed rice
compani announc leigh ann pusey join lilli
senior vice presid corpor affair commun effect june
member lilli execut committe report
directli presid chief execut offic david rick pusey
current serv presid ceo american insur associ
compani keep target peer
ep estim faster growth ep vs
ahead estim mainli cost cut sale rose
volum gain solid sale new product trulic taltz
partial off-set modest declin ciali alimta complet
acquisit colucid pharmaceut includ phase compound
lasmiditan treat migrain provid timelin
baricitinib recent receiv non-approv complet respons letter
fda /jeffrey loo cfa
compani partner nr receiv
complet respons letter non-approv baricitinib treat
rheumatoid arthriti fda request addit dose safeti data
believ requir new clinic trial push back potenti approv
year surpris view previous releas data
solid sinc baricitinib recent receiv eu approv although view
pipelin posit high profil disappoint pipelin
news past month solanezumab fail alzheim trial
analyst research note compani news
co appoint luca visini manag director india
oper appoint effect feb visini replac
edgard olaizola prior appoint visini work
senior director global market also work vulcan srl sara
italia spa comacsa sa
compani keep target
ep estim tax reform benefit ep
vs ahead estim sale rose pharmaceut
sale driven strong sale new drug trulic taltz
jardianc top sell drug humalog ciali fell
respect humalog sale impact lower price due discount
rebat also concern declin anim health lower
volum market access headwind competit pressur posilac
compani announc appoint kimberli blackwel vice
presid earli phase develop immuno-oncolog march
dr blackwel current professor medicin assist professor
radiat oncolog duke univers medic center
compani announc philip johnson appoint senior
vice presid financ treasur effect januari johnson
current serv vice presid investor relat lilli
report joshua smiley becom senior vice presid chief
financi offic effect januari johnson continu lead
et cfra keep hold opinion share eli lilli
compani rais target peer
forward ep estim faster growth ep
vs in-lin estim rais ep
estim sale rose driven new
drug trulic taltz world-wide diabet sale rose
explor potenti spin-off sale expect
provid updat elanco sale
second largest anim health compani view potenti move posit
compani announc number leadership chang promot
sever experienc lilli leader execut role effect josh
smileyha promot senior vice presid chief financi offic
becom member lilli execut committe effect januari
lilli announc june derica rice lilli current cfo would retir
year-end skovronski ph promot senior vice
presid scienc technolog presid lilli research lab
becom member lilli execut committe chang effect
june myle neill promot senior vice presid
presid manufactur oper becom member lilli
presid chief inform offic name execut offic
join lilli execut committe effect januari posit
inform technolog function direct report ceo critic
given role digit technolog analyt play futur
healthcar addit appoint announc two senior leader
announc retir compani maria crow presid
manufactur oper retir decemb year
servic jan lundberg ph execut vice presid scienc
technolog presid lilli research lab retir end may
eight year lilli
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
compani
fiscal year analyst estim earn
usd fiscal year analyst estim
earn per share grow usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
compani
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut standard
 poor malaysia sdn bhd cfra malaysia certain research distribut
cfra uk limit cfra uk cfra uk cfra malaysia wholly-own
subsidiari cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
compani
